Pemetinib (pemetinib) analysis: drug properties, anti-cancer mechanism and applicable diseases

Pemigatinib, the common English name ispemigatinib, is a cutting-edge anti-cancer drug carefully developed by Incyte, which has brought new treatment prospects to many cancer patients. With its unique mechanism of action and clear therapeutic indications, this drug is gradually becoming an important option in anti-cancer treatment.

Pemetinib is classified as a protein kinase inhibitor. Its most notable feature is its ability to accurately block specific protein kinases, especially its highly effective inhibitory effect on fibroblast growth factor receptors (FGFRs). FGFRs are widely distributed on the surface of cancer cells and play a central role in the proliferation and metastasis of cancer cells. Pemetinib significantly curbs cancer progression by specifically inhibiting tyrosine kinase activity in FGFRs.

As a prescription drug, pemetinib is mainly used clinically to treat two specific cancers: one is for adult patients who have undergone FGFR2 fusion or other rearrangement treatment, targeting unresectable locally advanced or metastatic cholangiocarcinoma; the other is for the treatment of adult patients with relapsed or refractory MLNs, patients with FGFR1 rearrangements.

Currently in the Chinese market, pemetinib tablets (trade name Dabotan/PEMAZYRE) are officially sold in pharmacies. Patients need to buy it with a doctor's prescription, but it is expensive, with the price of each box reaching tens of thousands of yuan. For patients with limited budgets, generic drugs produced by Lucius Pharmaceuticals in Laos offer a more economical option, priced at less than 1,000 yuan per box. However, caution is required when purchasing overseas drugs. Patients should purchase through formal channels and carefully verify the authenticity of the drugs.

In short, pemetinib, as an innovative anti-cancer drug, provides a new treatment strategy for patients with cholangiocarcinoma and MLNs by precisely inhibitingFGFR activity.